SYDNEY, Australia, July 21 /Xinhua-PRNewswire-FirstCall/ -- Specialty pharmaceutical company Pharmaxis Ltd today announced that it has lodged the registration documents for marketing approval of its asthma management product, Aridol, with the Swiss regulatory agency for therapeutic products, Swissmedic. Aridol will be distributed by Trimedal AG, a specialist respiratory and allergy pharmaceutical company based in Zurich.
Dr Alan Robertson, Pharmaxis Chief Executive Officer said; “Several important clinical trials for Aridol have taken place in Switzerland and, as a result, respiratory physicians are enthusiastic to have Aridol available. Swiss registration will augment our regulatory coverage in Europe, and allow us to move forward uniformly with the marketing and sales activities for Aridol.”
Aridol is currently under review by the Swedish Medical Products Agency as part of the mutual recognition procedure that will enable Pharmaxis to sell Aridol throughout the European Union. Switzerland is not part of the European Union and new medicines are subject to separate regulatory review.
To find out more about Pharmaxis and Aridol, go to http://www.pharmaxis.com.au . CONTACT: Alan Robertson Pharmaxis Chief Executive Officer Tel: +61-2-9454-7202 Fax: +61-2-9451-3622 Website: www.pharmaxis.com.au Released through: United States: Brandon Lewis Trout Group Tel: +1-212-477-9007 Email: blewis@troutgroup.com Australia: Ashley Rambukwella Financial & Corporate Relations Pty Ltd. Tel: +61-2-8264-1004 or +61-407-231-282 Email: a.rambukwella@fcr.com.au
Pharmaxis Ltd
CONTACT: Alan Robertson of Pharmaxis, +61-2-9454-7200, +61-2-9451-3622; orBrandon Lewis of Trout Group for Pharmaxis, +1-212-477-9007, orblewis@troutgroup.com; or Ashley Rambukwella of Financial & CorporateRelations Pty Ltd. for Pharmaxis, +61-2-8264-1004, or +61-407-231-282, ora.rambukwella@fcr.com.au
Web site: http://www.pharmaxis.com.au/
